'Most lucrative inside tip of all time' leads to arrest of former hedge fund manager

By Larry Neumeister

Associated Press

Posted:
11/20/2012 11:24:08 AM PST

Updated:
11/20/2012 03:14:56 PM PST

Click photo to enlarge

U. S. Attorney for the Southern district of N.Y. Preet Bharara speaks at a news conference, Tuesday, Nov. 20, 2012, in New York. Mathew Martoma, a former hedge fund portfolio manager was arrested Tuesday on charges that he helped carry out the most lucrative insider trading scheme in U.S. history, enabling investment advisers and their hedge funds to make more than $276 million in illegal profits. (AP Photo/Louis Lanzano)

NEW YORK -- A former hedge fund portfolio manager was arrested Tuesday on charges that he helped deliver what a prosecutor said "what might be the most lucrative inside tip of all time," enabling investment advisers and their hedge funds to make more than $276 million in illegal profits.

Mathew Martoma was charged in U.S. District Court in Manhattan with conspiracy to commit securities fraud and two counts of securities fraud in a scheme that stretched from 2006 through July 2008 while he worked for CR Intrinsic Investors LLC of Stamford, Conn.

"The charges unsealed today describe cheating coming and going -- specifically, insider trading first on the long side, and then on the short side, on a scale that has no historical precedent," U.S. Attorney Preet Bharara said in a statement.

The FBI said the scheme developed after Martoma met a doctor in Manhattan involved in an Alzheimer's disease drug trial in October 2006. The FBI said in a criminal complaint that he later obtained confidential information related to the final results of a drug trial.

Martoma's attorney, Charles Stillman, called Martoma "an exceptional portfolio manager who succeeded through hard work and the dogged pursuit of information in the public domain. What happened today is only the beginning of a process that we are confident will lead to Mr. Martoma's full exoneration."

Advertisement

The Securities and Exchange Commission filed civil papers in the case against CR Intrinsic Investors, Mathew Martoma and Dr. Sidney Gilman. The civil complaint said the illegal money was earned in July 2008 when various hedge funds traded ahead of a negative public announcement involving the clinical trial results of an Alzheimer drug being jointly developed by Elan Corp. and Wyeth.

The SEC complaint said that Martoma, then a portfolio manager at CR Intrinsic, carried out the scheme with Gilman, a professor of neurology at the University of Michigan Medical School. The SEC said Gilman served as chairman of the Safety Monitoring Committee overseeing the clinical trial and was selected by Elan and Wyeth to present the final clinical trial results at a July 29, 2008 medical conference. Messages left with the University of Michigan Medical School were not immediately returned.

Gilman's lawyer, Marc Mukasey, said his client is cooperating with the SEC and the US Attorney's Office, and has entered into a non-prosecution agreement with federal prosecutors.

The SEC said that leaks by Martoma caused hedge fund portfolios managed by CR Intrinsic as well as hedge fund portfolios managed by an affiliated investment adviser to liquidate their combined long positions in Elan and Wyeth, worth more than $700 million. It said he also caused them to take substantial short positions and to sell more than $960 million in Elan and Wyeth securities in just over a week.

The massive repositioning, the SEC said, allowed CR Intrinsic and various hedge funds to collective reap illicit profits and avoid losses of over $276 million.

"As alleged, by cultivating and corrupting a doctor with access to secret drug data, Mathew Martoma and his hedge fund benefited from what might be the most lucrative inside tip of all time," Bharara said. "As Martoma allegedly got sneak peeks at drug data, he first recommended that the hedge fund build up a massive position in Elan and Wyeth stock, and then caused the fund to shed those shares after getting a secret look at the unexpectedly bad results of a clinical drug trial. And so, overnight, Martoma went from bull to bear."